Pharmacology of the phosphate binder, lanthanum carbonate - Wikidata - wikimedia - TriplyDB

Pharmacology of the phosphate binder, lanthanum carbonate

Pharmacology of the phosphate binder, lanthanum carbonate

http://www.wikidata.org/entity/Q34854318

about

Hyperphosphatemia Management in Patients with Chronic Kidney Disease A comparison of the long-term effects of lanthanum carbonate and calcium carbonate on the course of chronic renal failure in rats with adriamycin-induced nephropathy Lanthanum, constipation, bafflying X-rays and a perforated colonic diverticulum Phosphate: an old bone molecule but new cardiovascular risk factor.Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: a pilot study.Ferric citrate hydrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification.Effect of cross-linked chitosan iron (III) on vascular calcification in uremic rats The utility of the phosphate binder, ferric citrate hydrate (JTT-751), about phosphorus absorption-reducing effect in normal rats

P2860

Q26743842-F7AC0AEC-BDF7-4E0C-90FA-37CF9017BB22 Q35171681-54B2E16E-73DC-402F-90A8-7F0C7572872A Q35366628-7831453D-F5D7-47F1-AC55-28485BDB0C2C Q37492019-C1AAF492-498A-4BED-B074-A9CF140CB538 Q39430387-F9EB1F1C-6775-49BA-9DC6-D85D8AB6346B Q46915404-433F7CE6-9D22-4CB7-A8C4-B98D1880A103 Q57214099-7933FEEC-3DF4-48F8-9143-415C014E9F4D Q57216834-C1D14EA5-13F3-43EA-B779-DE5F64F41200

P2860

Pharmacology of the phosphate binder, lanthanum carbonate

http://www.wikidata.org/entity/Q34854318

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Pharmacology of the phosphate binder, lanthanum carbonate

@ast

Pharmacology of the phosphate binder, lanthanum carbonate

@en

Pharmacology of the phosphate binder, lanthanum carbonate

@nl

type

label

Pharmacology of the phosphate binder, lanthanum carbonate

@ast

Pharmacology of the phosphate binder, lanthanum carbonate

@en

Pharmacology of the phosphate binder, lanthanum carbonate

@nl

prefLabel

Pharmacology of the phosphate binder, lanthanum carbonate

@ast

Pharmacology of the phosphate binder, lanthanum carbonate

@en

Pharmacology of the phosphate binder, lanthanum carbonate

@nl

P1433

Q34854318-7025DC94-3610-480E-859D-29D32B5DA5B3

P1476

Q34854318-8B7A9FCE-03AF-4F35-8D38-30BDFE2AF991

P2093

Q34854318-767F2B96-204B-4742-BB37-C5CA94114C96

P2860

Q34854318-090AD221-191F-46F4-A409-A6C1239ED428

Q34854318-0BD52B58-6D04-41D9-B3D6-D4FC3EA07DB1

Q34854318-2BBACE29-E7D7-456D-B022-49B7CC083F17

Q34854318-323E8FCA-81FE-49AE-85BC-3A834890CBDB

Q34854318-43B49813-AA93-455F-A0ED-E1DC296EE110

Q34854318-607DE1AB-25DC-4E22-8FA1-EEC1DCB390FD

Q34854318-628FC5F7-D959-4822-8320-F1A91C392C9D

Q34854318-79664759-8EF8-4D4A-BE85-AB52B4DB12BD

Q34854318-9A7FD335-B7BE-4A06-A1F4-6DB360ED6EDA

Q34854318-9EDBA961-09FA-4598-99F8-3588DDA96290

P304

Q34854318-FFB24DB5-2FD7-4F33-9E85-8508198DC9ED

P31

Q34854318-027EA6E6-8EC4-40A0-BB93-5961446EE3FA

P356

Q34854318-93D4694E-9DAA-4B5D-A484-0CC6FB2695CE

P433

Q34854318-55CE9FCA-9949-49A3-A038-6FF270A18F61

P478

Q34854318-515B2D11-ADA5-4F57-9C9F-0F43B22B06AD

P577

Q34854318-83F06758-3B3B-4A15-B50C-630A7B8A5968

P5875

Q34854318-4FD2555B-0C02-4E63-962B-517028DD9F44

P698

Q34854318-201F3BD8-F82B-4215-A8C1-4A6C44A52C3F

P921

Q34854318-67FD02B9-F9D2-420E-BE91-918C7BED07D5

P932

Q34854318-A2547566-5044-44AB-B3D4-5DD6C8614BF8

P356

0886022X.2011.552821

P1433

P1476

Pharmacology of the phosphate binder, lanthanum carbonate

@en

P2093

Stephen J P Damment

http://www.w3.org/2001/XMLSchema#string

P2860

Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?

Studies of the ultrastructure and permeability of the blood-brain barrier in the developing corpus callosum in postnatal rat brain using electron dense tracers.

Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study.

First International Summit on Kidney Disease Prevention, 25-27 July 2002: consensus document.

Improving phosphate-binder therapy as a way forward.

Consistent control of mineral and bone disorder in incident hemodialysis patients

A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.

A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice.

Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study.

Sevelamer hydrochloride (Renagel), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency.

P304

217-224

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/0886022X.2011.552821

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49846651

http://www.w3.org/2001/XMLSchema#string

P698

21332344

http://www.w3.org/2001/XMLSchema#string

P921

P932

3082170

http://www.w3.org/2001/XMLSchema#string